Key facts
Key Figures 1998-1999
Recent Achievements
Solvay position on world markets
Growth in sales (1984-1998)
1999 sales breakdown by therapeutic area (in %)
Growth through existing products in 4 therapeutics areas

Key facts

Solvay Pharmaceuticals is a group of pharmaceutical companies, active in more than 30 countries.
With a turnover of 1,35 billion EUR Solvay Pharmaceuticals ranks in the top 40 of pharmaceutical companies
Solvay Pharmaceuticals is strongly established in Europe, in Canada and the United States, and now has own organizations in virtually all countries in Western, Central and Eastern Europe. We are rapidly expanding in the United States, Japan and the rest of Asia where distribution and marketing have been established.
Solvay Pharmaceuticals is active in the therapeutic areas of cardiology, gastroenterology, mental health and hormone replacement.
Solvay Pharmaceuticals is world market leader in pancreatic enzymes, irritable bowel syndrome and vertigo. It has a leading position in antidepressants, laxatives and hormone replacement therapy
Solvay Pharmaceuticals maintains a substantial investment in R&D. Around seventeen percent of annual sales, more than the industry average, is committed to research and development of innovative products.
Worldwide the Solvay Pharmaceuticals companies have more than 6000 employees.

[Back to top]
Key Figures 1998-1999
Strong growth of 16% in both sales and earnings. “Fast and profitable growth” strategy yields results.
Largest products were Luvox® (17% of the total), Estratest® (9% of the total), Creon® (8% of the total), Duphalac® (6% of the total), Serc® (5% of the total) and Duspatal® (4% of the total).

Sales generated by the Solvay Pharmaceuticals companies were up 16% this year. The strongest growing products were Prometrium® (up 387%), Pantoloc® (up 113%), Estratab® (up 68%), Femoston® (up 48%), Physiotens® (up 32%) and Estratest® (up 29%).

The countries showing strongest growth in 1999 were the US (up 21% to 33% of the total), Canada (up 34% to 3% of the total), Central and Eastern Europe (up 26% to 3% of the total) and Japan (up 1500% to 2% of the total). Despite the continuing pressure from Western European health authorities we continue to grow in our major markets.

EUR MILLION 1997 1998 1999 D 98/99
Sales 1,049 1,167 1,349 +16%
EBIT (1) 118 135 157 +16%
Depreciation 44 46 54 +17%
Capital expeditures 79 56 313 X5.6
R&D; 151 175 229 +31%
Headcount (2) 6,172 6,235 6,694 +7%

(1) EBIT: earnings before net debt expense, taxes and non-allocated
(2) At January 1 of the following year
[Back to top]

Recent Achievements

Cardiology portfolio expanded by 2 major acquisitions, TEVETEN® (from SmithKlineBeecham) worldwide and ACEON® (from Servier) for the US.
Acquisition of 100% of Unimed Pharmaceuticals Inc. in the US.
An equity investment in and co-promotion deal with Duramed Pharmaceuticals Inc. in the US.
Creation of two additional field-forces (Solvay Pharmaceuticals and Unimed Pharmaceuticals) for promoting to primary care physicians and internists in the US.
Building of own organizations in Scandinavia.
Further investments in Eastern Europe with new organizations starting up in Latvia, Uzbekistan and Kazakhstan. Sales double in Slovakia, Poland and the Czech Republic.
Host partnership was signed in China with Tianjin-Hexal, a Chinese-German joint venture, to speed our growth.
An agreement was reached in India to concentrate our pharmaceutical business under the Solvay flag.
Acquisition and launch of PROMETRIUM® for hormone replacement therapy in the US.
Acquisition of Estrogel, Hormone replacement product under development in the US.
Acquisition of estrogen-progestin combination transdermal patch in the US.
US launch of the medication ESTRATAB® to prevent osteoporosis.
Successful launch in Japan of the first SSRI antidepressant and anti-obsessive compulsive disorder therapy, Solvay’s fluvoxamine, under trade marks LUVOX® (by Fujisawa and Solvay Seiyaku) and DEPROMEL® (by Meiji-Seika).
Alliance with Innogenetics in biotechnology.
Collaboration with BERNA (Switzerland) on a new influenza vaccine.
Specialization of plants in Europe, the US and Japan to cut manufacturing costs.
Restructuring of R&D to shorten the development process and ensure that our research centers in Europe, the United States and Japan share the same approach.
Enzyme activities sold to Genencor during the second quarter of 1998.
Animal health division sold to American Home products in 1998.

[Back to top]

Pancreatic Enzymes 1 1 2
Irritable Bowel Syndrome 1 1
Laxatives 2 1
Hormone Replacement Therapy 3 4 2
Vertigo (Menière’s disease) 1 1
Antidepressants/ OCD 10 12 8

[Back to top]

Growth in sales (1984-1999) in millions of EUR

in 1999: 1,349 millions of EUR
Activities sold in 1995 and 1996 [Back to top]

1999 sales breakdown by therapeutic area (in %) [Back to top]

Geographic breakdown of sales in 1999 (in %)

European Union 44%
Other European countries 10%
Nafta 38%
Mercosur <1%
Africa – Middle-East 4%
Asia – Pacific (including Japan) 4%

Total sales in 1999: EUR 1,349 M (USD 1,355 M) [Back to top]

Growth through existing products in 4 therapeutics areas:

Gastroenterology e.g. CREON® DICETEL® 428 128 31 + 5% + 13% + 6%
Psychiatry e.g. LUVOX® 370 228 + 14% + 22%
Hormone replacement therapies e.g. ESTRATEST® ESTRATAB® PROMETRIUM® 389 124 33 25 + 24% + 29% + 68% > 100%
Cardiology e.g. TEVETEN® ACEON® Physiotens 99 About 20 Mio EUR in Q4/99 31 + 37% –
+ 32%

[Back to top]

Leave a comment

Your email address will not be published. Required fields are marked *